Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Natera, Inc.

< Previous 1 2 3 Next >
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Provides Update on Ravgen Trial
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
From Natera, Inc.
Via Business Wire
Tickers NTRA
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Real-World Data Collaboration with Merck
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Third Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in November Investor Conferences
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
From Natera, Inc.
Via Business Wire
Tickers NTRA
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Report its Third Quarter 2023 Results on November 8
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
From Natera, Inc.
Via Business Wire
Tickers NTRA
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
From Natera, Inc.
Via Business Wire
Tickers NTRA
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Submits First PMA Module to the FDA for Signatera™
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Senior Leadership Appointments
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Pricing of $250 Million Follow-On Offering
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Launches Proposed Follow-On Offering
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Second Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Files Patent Infringement Suit Against NeoGenomics
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.